Neok Bio launches with $75M to make dual-targeting ADCs

▤ Summary

Neok Bio has launched with $75 million in Series A funding to develop dual-targeting antibody-drug conjugates for cancer treatment. The company plans to advance a pipeline of bispecific ADCs that aim at paired tumor targets such as B7-H3/ROR1 and EGFR/MUC1. Neok says its approach could improve efficacy and safety versus conventional ADCs by using dual targeting and specialized linker technology. The financing will support human testing for its lead programs next year, with early results expected in 2027. The company also plans to expand in the U.S. as it builds out the business.

$ Funding

▦ Linked Companies